Top

Open Access 16-05-2024 | Metabolic Dysfunction-Associated Steatotic Liver Disease | EM - ORIGINAL

Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study

Authors: Mario Masarone, Benedetta Maria Motta, Pietro Torre, Marco Aquino, Federica Belladonna, Martina Lombardi, Jacopo Troisi, Marcello Persico

Published in: Internal and Emergency Medicine

Abstract

Metabolic associated steatotic liver disease (MASLD) is the most common liver condition. It is associated with increased liver-related morbidity and mortality, and also with high risk of cardiovascular events (CVD), representing itself an independent risk factor for it. This makes MASLD a presentation of high interest for internal medicine, also because of its association with metabolic syndrome (MetS). It is crucial to assess its risks in a noninvasive way. With the aim of finding specific risk profiles for CVD development in MASLD by performing a noninvasive assessment of: (1) preclinical signs of endothelial dysfunction (ED); (2) clinical assessment of CVD risk by Framingham Heart Risk Score (FHRs); (3) genomic characterization of MASLD associated polymorphisms; (4) specific untargeted metabolomic profiles, we enrolled 466 MASLD patients non-invasively classified in 4 group of liver fibrosis severity (group-A: low-fibrosis risk, group-B: high-fibrosis risk, group-C: MASLD-cirrhosis, group-D: MASLD-HCC) and 73 healthy controls. FHRs was similar in controls and low-fibrosis group and significantly higher in high-fibrosis patients, cirrhosis, and HCC, increasing among classes. At a multivariable regression, FHRs was associated with liver disease severity and diabetes. 38.2% of patients had altered EndoPAT, resembling ED. Patients with high FHRs (> 40%) and ED had different metabolomics compared to those without ED. Our study reveals that a deep, non-invasive characterization of MASLD patients through precision medicine approaches (untargeted metabolomics, SNPs, ED assessment) was able to show a peculiar pattern in MASLD patients with increased CVD risk, mostly correlated with liver disease severity.

Graphical abstract

Available only for authorised users

Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M (2014) Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials 9(3):126–133. https://doi.org/10.2174/1574887109666141216111143CrossRefPubMed

Marchesini G, Bugianesi E, Burra P, Marra F, Miele L, Alisi A et al (2022) Non-alcoholic fatty liver disease in adults 2021: a clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Dig Liver Dis 54(2):170–182. https://doi.org/10.1016/j.dld.2021.04.029CrossRef

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1):73–84. https://doi.org/10.1002/hep.28431CrossRefPubMed

Eslam M, Sanyal AJ, George J, International Consensus P (2020) MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158(7):1999 e1-2014 e1. https://doi.org/10.1053/j.gastro.2019.11.312CrossRef

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al (2023) A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. https://doi.org/10.1016/j.jhep.2023.06.003CrossRefPubMed

Bhatia LS, Curzen NP, Calder PC, Byrne CD (2012) Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 33(10):1190–1200. https://doi.org/10.1093/eurheartj/ehr453CrossRefPubMed

Lonardo A, Nascimbeni F, Mantovani A, Targher G (2018) Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol 68(2):335–352. https://doi.org/10.1016/j.jhep.2017.09.021CrossRefPubMed

Younossi Z, Henry L (2016) Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology 150(8):1778–1785. https://doi.org/10.1053/j.gastro.2016.03.005CrossRefPubMed

Targher G, Byrne CD, Tilg H (2024) MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. https://doi.org/10.1136/gutjnl-2023-330595CrossRefPubMed

10.

Grgurevic I, Podrug K, Mikolasevic I, Kukla M, Madir A, Tsochatzis EA (2020) Natural history of nonalcoholic fatty liver disease: implications for clinical practice and an individualized approach. Can J Gastroenterol Hepatol 2020:1–10. https://doi.org/10.1155/2020/9181368CrossRef

11.

Tincopa MA, Loomba R (2023) Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol 8(7):660–670. https://doi.org/10.1016/s2468-1253(23)00066-3CrossRefPubMed

12.

Chow KW, Futela P, Saharan A, Saab S (2023) Comparison of guidelines for the screening, diagnosis, and non-invasive assessment of non-alcoholic fatty liver disease. J Clin Exp Hepatol. https://doi.org/10.1016/j.jceh.2023.01.016CrossRefPubMed

13.

Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97(18):1837–1847. https://doi.org/10.1161/01.Cir.97.18.1837CrossRefPubMed

14.

D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM et al (2008) General cardiovascular risk profile for use in primary care. Circulation 117(6):743–753. https://doi.org/10.1161/circulationaha.107.699579CrossRefPubMed

15.

Collins DRJ, Tompson AC, Onakpoya IJ, Roberts N, Ward AM, Heneghan CJ (2017) Global cardiovascular risk assessment in the primary prevention of cardiovascular disease in adults: systematic review of systematic reviews. BMJ Open. https://doi.org/10.1136/bmjopen-2016-013650CrossRefPubMedPubMedCentral

16.

Hamburg NM, Keyes MJ, Larson MG, Vasan RS, Schnabel R, Pryde MM et al (2008) Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham heart study. Circulation 117(19):2467–2474. https://doi.org/10.1161/circulationaha.107.748574CrossRefPubMedPubMedCentral

17.

Hamburg NM, Palmisano J, Larson MG, Sullivan LM, Lehman BT, Vasan RS et al (2011) Relation of brachial and digital measures of vascular function in the community. Hypertension 57(3):390–396. https://doi.org/10.1161/hypertensionaha.110.160812CrossRefPubMed

18.

Cooper LL, Wang N, Beiser AS, Romero JR, Aparicio HJ, Lioutas V-A et al (2021) Digital peripheral arterial tonometry and cardiovascular disease events: the Framingham heart study. Stroke 52(9):2866–2873. https://doi.org/10.1161/strokeaha.120.031102CrossRefPubMedPubMedCentral

19.

Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40(12):1461–1465. https://doi.org/10.1038/ng.257CrossRefPubMedPubMedCentral

20.

Singal AG, Manjunath H, Yopp AC, Beg MS, Marrero JA, Gopal P et al (2014) The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol 109(3):325–334. https://doi.org/10.1038/ajg.2013.476CrossRefPubMedPubMedCentral

21.

Eslam M, Valenti L, Romeo S (2018) Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 68(2):268–279. https://doi.org/10.1016/j.jhep.2017.09.003CrossRefPubMed

22.

Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E et al (2015) Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 61(2):506–514. https://doi.org/10.1002/hep.27490CrossRefPubMed

23.

Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta R et al (2016) The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology 150(5):1219–30.e6. https://doi.org/10.1053/j.gastro.2016.01.032CrossRefPubMed

24.

Donati B, Dongiovanni P, Romeo S, Meroni M, McCain M, Miele L et al (2017) MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Sci Rep. https://doi.org/10.1038/s41598-017-04991-0CrossRefPubMedPubMedCentral

25.

Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PRV, Orho-Melander M et al (2009) The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 18(21):4081–4088. https://doi.org/10.1093/hmg/ddp357CrossRefPubMedPubMedCentral

26.

Patti GJ, Yanes O, Siuzdak G (2012) Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 13(4):263–269. https://doi.org/10.1038/nrm3314CrossRefPubMedPubMedCentral

27.

Masarone M, Troisi J, Aglitti A, Torre P, Colucci A, Dallio M et al (2021) Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. Metabolomics. https://doi.org/10.1007/s11306-020-01756-1CrossRefPubMed

28.

Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M et al (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 33(13):1635–1701. https://doi.org/10.1093/eurheartj/ehs092CrossRefPubMed

29.

Axtell AL, Gomari FA, Cooke JP (2010) Assessing endothelial vasodilator function with the Endo-PAT 2000. J Vis Exp. https://doi.org/10.3791/2167CrossRefPubMedPubMedCentral

30.

Troisi J, Sarno L, Martinelli P, Di Carlo C, Landolfi A, Scala G et al (2017) A metabolomics-based approach for non-invasive diagnosis of chromosomal anomalies. Metabolomics. https://doi.org/10.1007/s11306-017-1274-zCrossRef

31.

Troisi J, Pierri L, Landolfi A, Marciano F, Bisogno A, Belmonte F et al (2017) Urinary metabolomics in pediatric obesity and NAFLD identifies metabolic pathways/metabolites related to dietary habits and gut-liver axis perturbations. Nutrients. https://doi.org/10.3390/nu9050485CrossRefPubMedPubMedCentral

32.

Wehrens R, Bloemberg TG, Eilers PHC (2015) Fast parametric time warping of peak lists: Fig. 1. Bioinformatics 31(18):3063–3065. https://doi.org/10.1093/bioinformatics/btv299CrossRefPubMed

33.

van den Berg RA, Hoefsloot HCJ, Westerhuis JA, Smilde AK, van der Werf MJ (2006) Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genom. https://doi.org/10.1186/1471-2164-7-142CrossRef

34.

Whitley D (1994) A genetic algorithm tutorial. Stat Comput. https://doi.org/10.1007/bf00175354CrossRef

35.

Bijlsma S, Bobeldijk I, Verheij ER, Ramaker R, Kochhar S, Macdonald IA et al (2005) Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. Anal Chem 78(2):567–574. https://doi.org/10.1021/ac051495jCrossRef

36.

Domingos P (1999) MetaCost: a general method for making classifiers cost-sensitive. In: Proceedings of the fifth ACM SIGKDD international conference on knowledge discovery and data mining, pp 155–164

37.

Wold S, Sjostrom M, Eriksson L (2002) Partial least squares projections to latent structures (PLS) in chemistry. Encyclopedia of computational chemistry 3. https://doi.org/10.1002/0470845015.cpa012

38.

Byrne CD, Targher G (2015) NAFLD: a multisystem disease. J Hepatol 62(1):S47–S64. https://doi.org/10.1016/j.jhep.2014.12.012CrossRefPubMed

39.

Targher G, Byrne CD, Tilg H (2020) NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 69(9):1691–1705. https://doi.org/10.1136/gutjnl-2020-320622CrossRefPubMed

40.

Targher G, Corey KE, Byrne CD (2021) NAFLD, and cardiovascular and cardiac diseases: factors influencing risk, prediction and treatment. Diabetes Metab. https://doi.org/10.1016/j.diabet.2020.101215CrossRefPubMed

41.

Poredos P, Poredos AV, Gregoric I (2021) Endothelial dysfunction and its clinical implications. Angiology 72(7):604–615. https://doi.org/10.1177/0003319720987752CrossRefPubMed

42.

Aune D, Keum N, Giovannucci E, Fadnes LT, Boffetta P, Greenwood DC et al (2018) Dietary intake and blood concentrations of antioxidants and the risk of cardiovascular disease, total cancer, and all-cause mortality: a systematic review and dose–response meta-analysis of prospective studies. Am J Clin Nutr 108(5):1069–1091. https://doi.org/10.1093/ajcn/nqy097CrossRefPubMedPubMedCentral

43.

Dong X, Zhou W, Li H, Fan Y, Yin X, Li Y et al (2019) Plasma metabolites mediate the effect of HbA1c on incident cardiovascular disease. Clin Cardiol 42(10):934–941. https://doi.org/10.1002/clc.23243CrossRefPubMedPubMedCentral

44.

Mao B, Yi Y, Mo Q, Yang C, Zhong Q (2019) Metabolic profiling reveals the heterogeneity of vascular endothelial function phenotypes in individuals at extreme cardiovascular risk. RSC Adv 9(52):30033–30044. https://doi.org/10.1039/c9ra05526fCrossRefPubMedPubMedCentral

45.

Amiri P, Hosseini SA, Ghaffari S, Tutunchi H, Ghaffari S, Mosharkesh E et al (2022) Role of butyrate, a gut microbiota derived metabolite, in cardiovascular diseases: a comprehensive narrative review. Front Pharmacol. https://doi.org/10.3389/fphar.2021.837509CrossRefPubMedPubMedCentral

46.

Fillmore N, Mori J, Lopaschuk GD (2014) Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br J Pharmacol 171(8):2080–2090. https://doi.org/10.1111/bph.12475CrossRefPubMedPubMedCentral

47.

Tzoulaki I, Castagné R, Boulangé CL, Karaman I, Chekmeneva E, Evangelou E et al (2019) Serum metabolic signatures of coronary and carotid atherosclerosis and subsequent cardiovascular disease. Eur Heart J 40(34):2883–2896. https://doi.org/10.1093/eurheartj/ehz235CrossRefPubMedPubMedCentral

48.

Patel A, Thompson A, Abdelmalek L, Adams-Huet B, Jialal I (2019) The relationship between tyramine levels and inflammation in metabolic syndrome. Hormone Mol Biol Clin Investig. https://doi.org/10.1515/hmbci-2019-0047CrossRef

49.

Omori K, Katakami N, Yamamoto Y, Ninomiya H, Takahara M, Matsuoka T-A et al (2019) Identification of metabolites associated with onset of CAD in diabetic patients using CE-MS analysis: a pilot study. J Atheroscler Thrombosis 26(3):233–245. https://doi.org/10.5551/jat.42945CrossRef

50.

Li N, Wang Y, Zhou J, Chen R, Li J, Zhao X et al (2022) Association between the changes in trimethylamine N-oxide-related metabolites and prognosis of patients with acute myocardial infarction: a prospective study. J Cardiovasc Dev Dis. https://doi.org/10.3390/jcdd9110380CrossRefPubMedPubMedCentral

51.

Razquin C, Ruiz-Canela M, Clish CB, Li J, Toledo E, Dennis C et al (2019) Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies. Cardiovasc Diabetol. https://doi.org/10.1186/s12933-019-0958-2CrossRefPubMedPubMedCentral

52.

Alam YH, Kim R, Jang C (2022) Metabolism and health impacts of dietary sugars. J Lipid Atheroscler. https://doi.org/10.12997/jla.2022.11.1.20CrossRefPubMedPubMedCentral

53.

Razquin C, Ruiz-Canela M, Toledo E, Clish CB, Guasch-Ferré M, García-Gavilán JF et al (2022) Circulating amino acids and risk of peripheral artery disease in the PREDIMED trial. Int J Mol Sci. https://doi.org/10.3390/ijms24010270CrossRefPubMedPubMedCentral

54.

Luukkonen PK, Qadri S, Ahlholm N, Porthan K, Männistö V, Sammalkorpi H et al (2022) Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. J Hepatol 76(3):526–535. https://doi.org/10.1016/j.jhep.2021.10.013CrossRefPubMedPubMedCentral

55.

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M et al (2021) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42(34):3227–3337. https://doi.org/10.1093/eurheartj/ehab484CrossRefPubMed

Title: Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study
Authors: Mario Masarone
Benedetta Maria Motta
Pietro Torre
Marco Aquino
Federica Belladonna
Martina Lombardi
Jacopo Troisi
Marcello Persico
Publication date: 16-05-2024
Publisher: Springer International Publishing
Keyword: Metabolic Dysfunction-Associated Steatotic Liver Disease
Published in: Internal and Emergency Medicine
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-024-03626-3

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ESC Congress

Springer Medicine

Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study

Abstract

Graphical abstract

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials

2024 ESC Congress

Springer Medicine

Abstract

Graphical abstract

Please log in to get access to this content

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials